spacer
home > epc > spring 2019 > smarter supply chains
PUBLICATIONS
European Pharmaceutical Contractor

Smarter Supply Chains

The role of the supply chain in protecting patients from unsafe medical products is crucial, with the transportation and storage of pharmaceuticals having a significant impact on product integrity. However, with the growth of biopharmaceuticals, the significance of getting logistics right becomes even more important. The stricter logistical requirements and significant costs are combined with limited supply, meaning that every batch is vital. This article will consider how supply chains can work smarter to mitigate the risks that cause product failures and better protect end-patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
James Colson has principally worked in the European road sector, including both own accounts and third party. More recently, this has expanded to air and ocean environments too, with a focus on healthcare solutions for pharmaceutical customers. James' in-depth knowledge has led to him heading up the internal Yusen team that is focused on Brexit, and the impacts and implications for both Yusen and our customers.

Ellena Austin has carved a career in Marketing with a vast range of experience from fashion PR to corporate events and copywriting for a number of verticals including Healthcare, Consumer Electronics and White Goods. Currently working as Marketing Executive for Yusen Logistics UK, Ellena executes the UK marketing strategy in line with regional and global directives. Within her company she holds Regional Brand Ambassador and Regional Connected Ambassador roles, representing the EU region.
spacer
Ellena Austin
spacer
spacer
spacer
James Colson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement